These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34942275)

  • 21. Evaluation of (64)Cu-labeled DOTA-D-Phe(1)-Tyr (3)-octreotide ((64)Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors.
    Hanaoka H; Tominaga H; Yamada K; Paudyal P; Iida Y; Watanabe S; Paudyal B; Higuchi T; Oriuchi N; Endo K
    Ann Nucl Med; 2009 Aug; 23(6):559-67. PubMed ID: 19504168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology.
    Rowe-Rendleman CL
    Pharm Res; 2019 Feb; 36(4):54. PubMed ID: 30790065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine: a clarification.
    Kroiss A; Putzer D; Uprimny C; Decristoforo C; Gabriel M; Santner W; Kranewitter C; Warwitz B; Waitz D; Kendler D; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):543. PubMed ID: 22237841
    [No Abstract]   [Full Text] [Related]  

  • 24. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients.
    Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A
    J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.
    Alexander N; Vali R; Ahmadzadehfar H; Shammas A; Baruchel S
    Curr Radiopharm; 2018; 11(1):14-21. PubMed ID: 29243585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo molecular imaging biomarkers: clinical pharmacology's new "PET"?
    Nutt R; Vento LJ; Ridinger MH
    Clin Pharmacol Ther; 2007 Jun; 81(6):792-5. PubMed ID: 17505491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gadofosveset: MS 325, MS 32520, Vasovist, ZK 236018.
    Drugs R D; 2004; 5(6):339-42. PubMed ID: 15563237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to Single Low-dose
    Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X
    Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731
    [No Abstract]   [Full Text] [Related]  

  • 29. Molecular Imaging in Drug Discovery and Development.
    Lindner JR; Link J
    Circ Cardiovasc Imaging; 2018 Feb; 11(2):e005355. PubMed ID: 29449411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular imaging of carcinoid.
    Jindal T; Kumar A; Dutta R; Gupta R; Kumar R
    Hell J Nucl Med; 2009; 12(2):168-9. PubMed ID: 19675874
    [No Abstract]   [Full Text] [Related]  

  • 31. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
    Breeman WA; de Blois E; Sze Chan H; Konijnenberg M; Kwekkeboom DJ; Krenning EP
    Semin Nucl Med; 2011 Jul; 41(4):314-21. PubMed ID: 21624565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography molecular imaging for drug development.
    Matthews PM; Rabiner EA; Passchier J; Gunn RN
    Br J Clin Pharmacol; 2012 Feb; 73(2):175-86. PubMed ID: 21838787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.
    Hubble D; Kong G; Michael M; Johnson V; Ramdave S; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2010 Oct; 37(10):1869-75. PubMed ID: 20445977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Mueller-Brand J; Paganelli G; Anthony LB; Pauwels S; Kvols LK; O'dorisio TM; Valkema R; Bodei L; Chinol M; Maecke HR; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():62S-6S. PubMed ID: 15653653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alzheimer's imaging agents struggle to find a market outside trials.
    Williams SC
    Nat Med; 2013 Dec; 19(12):1551. PubMed ID: 24309640
    [No Abstract]   [Full Text] [Related]  

  • 36. An imaging agent for amyloid.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):54-5. PubMed ID: 22777304
    [No Abstract]   [Full Text] [Related]  

  • 37. Could 68Ga-somatostatin analogues replace other PET tracers in evaluating extra-adrenal paragangliomas?
    Treglia G; Giovanella L
    Eur J Nucl Med Mol Imaging; 2013 Dec; 40(12):1797-9. PubMed ID: 24072348
    [No Abstract]   [Full Text] [Related]  

  • 38. Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model.
    Petersen AL; Binderup T; Jølck RI; Rasmussen P; Henriksen JR; Pfeifer AK; Kjær A; Andresen TL
    J Control Release; 2012 Jun; 160(2):254-63. PubMed ID: 22245688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positron-emission tomography molecular imaging of glia and myelin in drug discovery for multiple sclerosis.
    Matthews PM; Datta G
    Expert Opin Drug Discov; 2015 May; 10(5):557-70. PubMed ID: 25843125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.